Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 743585
                    [Title] => Roche launches  drug for advanced  ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 742896
                    [Title] => First-line treatment for advanced ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 703067
                    [Title] => Roche's drug receives broader EU label  for women with metastatic breast cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
                    [DatePublished] => 2011-07-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 696213
                    [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
                    [Summary] => 
Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
                    [DatePublished] => 2011-06-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 657719
                    [Title] => Treatment helps women with ovarian cancer live significantly longer
                    [Summary] => 
Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
                    [DatePublished] => 2011-02-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 602911
                    [Title] => Roche's Bevacizumab Offers Hope to Brain Cancer Patients
                    [Summary] => 
After over a decade that saw no new effective therapy developed for the most common and aggressive form of brain cancer, Roche’s bevacizumab now offers hope to patients with recurrent or progressive glioblastoma (GBM).
                    [DatePublished] => 2010-08-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Freeman Cebu Lifestyle
                    [SectionUrl] => cebu-lifestyle
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 601474
                    [Title] => Roche drug shows longest overall survival  for patients with advanced lung cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced updated results from a late-stage study demonstrating that first-line use of bevacizumab provided the longest median overall survival duration shown in a Phase III trial of patients with advanced non-small cell adenocarcinoma of the lung.
                    [DatePublished] => 2010-08-12 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 599398
                    [Title] => Roche drug helps women with ovarian cancer live longer
                    [Summary] => 
BASEL, Switzerland — Roche announced recently that a second large, phase  III, international study showed that the combination of bevacizumab and  chemotherapy followed by the continued use of bevacizumab alone...
                    [DatePublished] => 2010-08-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 588820
                    [Title] => Roche drug helps women with ovarian cancer live longer
                    [Summary] => 
Roche recently announced results from a Phase III study of bevacizumab that showed women with previously untreated advanced ovarian cancer who received bevacizumab in combination with chemotherapy, followed by the continuation of bevacizumab alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.
                    [DatePublished] => 2010-07-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

BEVACIZUMAB

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 743585
                    [Title] => Roche launches  drug for advanced  ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 742896
                    [Title] => First-line treatment for advanced ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 703067
                    [Title] => Roche's drug receives broader EU label  for women with metastatic breast cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
                    [DatePublished] => 2011-07-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 696213
                    [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
                    [Summary] => 
Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
                    [DatePublished] => 2011-06-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 657719
                    [Title] => Treatment helps women with ovarian cancer live significantly longer
                    [Summary] => 
Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
                    [DatePublished] => 2011-02-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 602911
                    [Title] => Roche's Bevacizumab Offers Hope to Brain Cancer Patients
                    [Summary] => 
After over a decade that saw no new effective therapy developed for the most common and aggressive form of brain cancer, Roche’s bevacizumab now offers hope to patients with recurrent or progressive glioblastoma (GBM).
                    [DatePublished] => 2010-08-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Freeman Cebu Lifestyle
                    [SectionUrl] => cebu-lifestyle
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 601474
                    [Title] => Roche drug shows longest overall survival  for patients with advanced lung cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced updated results from a late-stage study demonstrating that first-line use of bevacizumab provided the longest median overall survival duration shown in a Phase III trial of patients with advanced non-small cell adenocarcinoma of the lung.
                    [DatePublished] => 2010-08-12 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 599398
                    [Title] => Roche drug helps women with ovarian cancer live longer
                    [Summary] => 
BASEL, Switzerland — Roche announced recently that a second large, phase  III, international study showed that the combination of bevacizumab and  chemotherapy followed by the continued use of bevacizumab alone...
                    [DatePublished] => 2010-08-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 588820
                    [Title] => Roche drug helps women with ovarian cancer live longer
                    [Summary] => 
Roche recently announced results from a Phase III study of bevacizumab that showed women with previously untreated advanced ovarian cancer who received bevacizumab in combination with chemotherapy, followed by the continuation of bevacizumab alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.
                    [DatePublished] => 2010-07-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest